Revenues (Details Textual) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Revenues	$ 3,671.3	$ 3,600.1	$ 3,616.7	$ 3,489.8	$ 3,526.3	$ 3,439.0	$ 3,356.5	$ 3,131.1	$ 14,377.9	$ 13,452.9	$ 12,273.9
Revenues In Percentage From Anti-CD20 Therapeutic Programs									16.00%	15.00%	13.00%
Distributor One
Disaggregation of Revenue [Line Items]
Percentage of revenue from major distributors									30.00%	32.00%	34.00%
Percentage receivables of wholesale distributor accounted in consolidated receivables	24.10%				27.70%				24.10%	27.70%
Distributor Two
Disaggregation of Revenue [Line Items]
Percentage of revenue from major distributors									17.00%	18.00%	21.00%
Percentage receivables of wholesale distributor accounted in consolidated receivables	13.90%				15.60%				13.90%	15.60%
Other revenue
Disaggregation of Revenue [Line Items]
Revenues	$ 145.7	$ 109.6	$ 160.0	$ 292.4	$ 165.7	$ 147.2	$ 108.6	$ 164.4	$ 707.7	$ 585.9	$ 360.0
Other revenue | Bioverativ
Disaggregation of Revenue [Line Items]
Revenues									383.2	206.7	64.8
Other corporate revenues
Disaggregation of Revenue [Line Items]
Revenues									584.5	$ 459.4	$ 253.7
Revenue, Remaining Performance Obligation, Amount	$ 500.0								$ 500.0